JP2002531520A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002531520A5 JP2002531520A5 JP2000586359A JP2000586359A JP2002531520A5 JP 2002531520 A5 JP2002531520 A5 JP 2002531520A5 JP 2000586359 A JP2000586359 A JP 2000586359A JP 2000586359 A JP2000586359 A JP 2000586359A JP 2002531520 A5 JP2002531520 A5 JP 2002531520A5
- Authority
- JP
- Japan
- Prior art keywords
- immunotherapeutic agent
- cell line
- atcc crl
- derived
- prostate cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002955 immunomodulating agent Substances 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 15
- 239000000203 mixture Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 8
- 206010060862 Prostate cancer Diseases 0.000 description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000012646 vaccine adjuvant Substances 0.000 description 3
- 229940124931 vaccine adjuvant Drugs 0.000 description 3
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000008150 cryoprotective solution Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 210000005267 prostate cell Anatomy 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 241001446247 uncultured actinomycete Species 0.000 description 2
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 229940100994 interleukin-7 Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9827104.2A GB9827104D0 (en) | 1998-12-10 | 1998-12-10 | New cancer treatments |
| GB9827104.2 | 1998-12-10 | ||
| PCT/GB1999/004129 WO2000033869A2 (en) | 1998-12-10 | 1999-12-09 | Use of human prostrate cell lines in cancer treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011223318A Division JP2012021028A (ja) | 1998-12-10 | 2011-10-07 | ガンの新規処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002531520A JP2002531520A (ja) | 2002-09-24 |
| JP2002531520A5 true JP2002531520A5 (enExample) | 2006-12-28 |
| JP4949554B2 JP4949554B2 (ja) | 2012-06-13 |
Family
ID=10843926
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000586359A Expired - Fee Related JP4949554B2 (ja) | 1998-12-10 | 1999-12-09 | ガンの新規処置 |
| JP2011223318A Pending JP2012021028A (ja) | 1998-12-10 | 2011-10-07 | ガンの新規処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011223318A Pending JP2012021028A (ja) | 1998-12-10 | 2011-10-07 | ガンの新規処置 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US6972128B1 (enExample) |
| EP (1) | EP1137422B1 (enExample) |
| JP (2) | JP4949554B2 (enExample) |
| KR (1) | KR20010090874A (enExample) |
| AT (1) | ATE304365T1 (enExample) |
| AU (1) | AU763485B2 (enExample) |
| CA (1) | CA2354045C (enExample) |
| CZ (1) | CZ300499B6 (enExample) |
| DE (1) | DE69927286T2 (enExample) |
| ES (1) | ES2249046T3 (enExample) |
| GB (1) | GB9827104D0 (enExample) |
| HU (1) | HUP0104568A3 (enExample) |
| IL (2) | IL143296A0 (enExample) |
| MX (1) | MXPA01005816A (enExample) |
| NO (1) | NO327044B1 (enExample) |
| NZ (1) | NZ512004A (enExample) |
| PL (1) | PL201016B1 (enExample) |
| WO (1) | WO2000033869A2 (enExample) |
| ZA (1) | ZA200104164B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9827103D0 (en) * | 1998-12-10 | 1999-02-03 | Onyvax Ltd | New cancer treatments |
| GB9827104D0 (en) * | 1998-12-10 | 1999-02-03 | Onyvax Ltd | New cancer treatments |
| AU4935700A (en) * | 1999-05-21 | 2000-12-12 | Onyvax Limited | New vaccine formulations-3 |
| US7303911B2 (en) * | 2000-04-01 | 2007-12-04 | Onyvax Limited | Prostate cell lines |
| US6667479B2 (en) * | 2001-06-01 | 2003-12-23 | Raytheon Company | Advanced high speed, multi-level uncooled bolometer and method for fabricating same |
| US20050019336A1 (en) * | 2003-07-23 | 2005-01-27 | Dalgleish Angus George | Human prostate cell lines in cancer treatment |
| EP1658078A4 (en) * | 2003-08-26 | 2009-05-06 | Becton Dickinson Co | PROCESS FOR THE INTRADERMAL DISTRIBUTION OF THERAPEUTIC AGENTS |
| CN101646455A (zh) | 2007-02-07 | 2010-02-10 | 财团法人阪大微生物病研究会 | 用于癌症的治疗剂 |
| JPWO2009066462A1 (ja) * | 2007-11-20 | 2011-04-07 | 日本電気株式会社 | 細胞傷害性ｔ細胞の誘導方法、細胞傷害性ｔ細胞の誘導剤、およびそれを用いた医薬組成物およびワクチン |
| AU2009200767A1 (en) * | 2008-03-10 | 2009-09-24 | Aristocrat Technologies Australia Pty Limited | A gaming system and a method of gaming |
| WO2010057197A1 (en) | 2008-11-17 | 2010-05-20 | The Regents Of The University Of Michigan | Cancer vaccine compositions and methods of using the same |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69232890T2 (de) * | 1991-10-04 | 2003-10-09 | The Johns Hopkins University School Of Medicine, Baltimore | Regulierung der systemischen immunantworten mittels zytokinen und antigenen |
| JPH05246889A (ja) * | 1992-03-05 | 1993-09-24 | Seitai Chiyousetsu Kenkyusho:Kk | 制癌方法および制癌剤 |
| AU2370195A (en) * | 1994-04-28 | 1995-11-29 | Scott Freeman | Cell lines obtained by (in vivo) migration and by fusion with autoimmune cells |
| ATE338813T1 (de) * | 1995-03-17 | 2006-09-15 | Univ California | Methode zur tumorbehandlung mit alloaktivierten humanen lymphozyen |
| US5788963A (en) * | 1995-07-31 | 1998-08-04 | Pacific Northwest Cancer Foundation | Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy |
| AU1355697A (en) * | 1995-12-28 | 1997-07-28 | Johns Hopkins University School Of Medicine, The | Allogeneic paracrine cytokine tumor vaccines |
| DE69721731T2 (de) * | 1996-02-02 | 2004-03-18 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Immortalisierte menschliche prostata-epithelzellen und klone und ihre verwendungen zur untersuchung und therapie von prostata-krebs |
| GB9620350D0 (en) * | 1996-09-30 | 1996-11-13 | Maudsley David J | Cancer vaccine |
| US6207805B1 (en) * | 1997-07-18 | 2001-03-27 | University Of Iowa Research Foundation | Prostate cell surface antigen-specific antibodies |
| GB9827104D0 (en) * | 1998-12-10 | 1999-02-03 | Onyvax Ltd | New cancer treatments |
-
1998
- 1998-12-10 GB GBGB9827104.2A patent/GB9827104D0/en not_active Ceased
-
1999
- 1999-12-09 PL PL348828A patent/PL201016B1/pl not_active IP Right Cessation
- 1999-12-09 AT AT99959542T patent/ATE304365T1/de not_active IP Right Cessation
- 1999-12-09 CA CA2354045A patent/CA2354045C/en not_active Expired - Fee Related
- 1999-12-09 ES ES99959542T patent/ES2249046T3/es not_active Expired - Lifetime
- 1999-12-09 JP JP2000586359A patent/JP4949554B2/ja not_active Expired - Fee Related
- 1999-12-09 NZ NZ512004A patent/NZ512004A/en unknown
- 1999-12-09 MX MXPA01005816A patent/MXPA01005816A/es active IP Right Grant
- 1999-12-09 HU HU0104568A patent/HUP0104568A3/hu unknown
- 1999-12-09 DE DE69927286T patent/DE69927286T2/de not_active Expired - Lifetime
- 1999-12-09 AU AU16683/00A patent/AU763485B2/en not_active Ceased
- 1999-12-09 IL IL14329699A patent/IL143296A0/xx active IP Right Grant
- 1999-12-09 KR KR1020017007096A patent/KR20010090874A/ko not_active Ceased
- 1999-12-09 US US09/857,691 patent/US6972128B1/en not_active Expired - Lifetime
- 1999-12-09 CZ CZ20012032A patent/CZ300499B6/cs not_active IP Right Cessation
- 1999-12-09 WO PCT/GB1999/004129 patent/WO2000033869A2/en not_active Ceased
- 1999-12-09 EP EP99959542A patent/EP1137422B1/en not_active Expired - Lifetime
-
2001
- 2001-05-22 IL IL143296A patent/IL143296A/en not_active IP Right Cessation
- 2001-05-22 ZA ZA200104164A patent/ZA200104164B/en unknown
- 2001-05-29 NO NO20012634A patent/NO327044B1/no not_active IP Right Cessation
-
2005
- 2005-07-12 US US11/178,415 patent/US8034360B2/en not_active Expired - Fee Related
-
2011
- 2011-10-07 JP JP2011223318A patent/JP2012021028A/ja active Pending
- 2011-10-11 US US13/270,820 patent/US20120164099A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002531521A5 (enExample) | ||
| CA2354046A1 (en) | New cancer treatments | |
| JP2012021028A5 (enExample) | ||
| Ellis | New technologies for making vaccines | |
| Senti et al. | Intralymphatic immunotherapy | |
| NO20015073D0 (no) | Vaksiner | |
| JP2002531520A5 (enExample) | ||
| Xiang et al. | Promising particle-based vaccines in cancer therapy | |
| JPH02504034A (ja) | 腫瘍転移の免疫療法のためのウイルス修飾腫瘍ワクチン | |
| AU2007309193B2 (en) | Extracellular matrix cancer vaccine adjuvant | |
| Yu et al. | Therapeutic dendritic cell vaccines engineered with antigen‐biomineralized Bi2S3 nanoparticles for personalized tumor radioimmunotherapy | |
| US20080260800A1 (en) | Extracellular matrix cancer vaccine adjuvant | |
| Gregoire et al. | Anti-cancer therapy using dendritic cells and apoptotic tumour cells: pre-clinical data in human mesothelioma and acute myeloid leukaemia | |
| Senti et al. | Intralymphatic immunotherapy: from the rationale to human applications | |
| Shah et al. | Immunizing cancer patients: which patients? Which vaccines? When to give? | |
| CA2354045A1 (en) | New cancer treatments | |
| Hrouda et al. | Mycobacterium vaccae (SRL172): a potential immunological adjuvant evaluated in rat prostate cancer | |
| Johansen et al. | Parenteral vaccine administration: tried and true | |
| WO2004002412A3 (en) | A method and composition to elicit an effective autologous antitumoral immune response in a patient | |
| Avent et al. | Non‐specific and specific active immunotherapy in a B16 murine melanoma system | |
| Bystryn | Immunosurveillance and melanoma | |
| JP5186678B2 (ja) | 経皮抗原投与のための抗原キット | |
| Reintgen et al. | Experimental trials of immunotherapy for malignant melanoma | |
| Wallack | A new approach in the immunotherapy of carcinoma of the colon and rectum | |
| Thosar¹ et al. | Vaccination in Children/Caries Vaccine |